Reframe Daily: One-shot syphilis treatment, safer clot care, and new insulin-making cells

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: One shot of penicillin worked as well as three for early syphilis; a lower long-term dose of the blood thinner apixaban helped people with cancer avoid clots; the PAH drug sotatercept improved patient outcomes; lab-grown insulin-making cells helped people with type 1 diabetes make insulin again; and donor insulin cells designed to “hide” from the immune system survived without daily anti-rejection drugs.

Christin’s note: today’s video is about how to balance our investigation into health optimization…with minimizing dependencies for our health (and happiness!) This is the main difference in philosophy between the reframe community and “biohacker” communities that I believe will help us achieve meaningful longevity.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A single shot of a cheap, widely available antibiotic worked as well as three shots to cure early syphilis—simpler, easier care.

One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis.

Market readiness: 🙂🙂🙂🙂🙂 (medicine already on U.S. shelves; regimen could shift quickly with guideline updates and clinician adoption). 

Good news: For people with cancer who’ve had a clot, a lower “extended” dose of apixaban kept protection while potentially reducing bleeding risk—easier long-term care.

Extended Reduced-Dose Apixaban for Cancer-Associated Thrombosis.

Market readiness: 🙂🙂🙂🙂🙂 (drug is already FDA-approved; this informs dosing many U.S. oncologists can use now as guidelines incorporate it). 

Good news: A PAH drug (sotatercept) improved outcomes in patients with serious lung-artery hypertension—adding a new, effective option.

Sotatercept in Patients with Pulmonary Arterial Hypertension.

Market readiness: 🙂🙂🙂🙂🙂 (therapy is FDA-approved; NEJM data support real-world adoption in U.S. centers). 

Good news: Lab-made insulin-making cells (from stem cells) helped people with type 1 diabetes make their own insulin again—pointing to future “cell replacement” therapy.

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes.

Market readiness: 🙂🙂 (early clinical trial; more studies, scaling, and safety follow-up needed before broad U.S. use). 

Good news: Donor beta cells engineered to hide from the immune system survived without ongoing anti-rejection drugs—hinting at maintenance-free diabetes cell therapy.

Survival of Transplanted Allogeneic Beta Cells with No Maintenance Immunosuppression.

Market readiness: 🙂 (first-in-human style evidence; promising but far from routine care yet in the U.S.)

Thank you for taking the time to take care of yourself and your loved ones.